Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000409884 | SCV000488233 | uncertain significance | Paragangliomas 5 | 2016-01-27 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002256224 | SCV002527705 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-03-02 | criteria provided, single submitter | curation | |
Labcorp Genetics |
RCV003766137 | SCV004581167 | uncertain significance | Mitochondrial complex II deficiency, nuclear type 1; Paragangliomas 5 | 2023-05-08 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SDHA protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. ClinVar contains an entry for this variant (Variation ID: 371819). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 454 of the SDHA protein (p.Ala454Thr). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SDHA-related conditions. |